Merck has partnered with Boston-based Dewpoint Therapeutics to develop a novel treatment for HIV.

Dewpoint is developing drugs based on biomolecular condensates within cells that it believes play a critical role in a wide range of disease processes, including viral infection.

The Boston company will receive up to $305 million in upfront and milestone payments, as well as royalties on future product sales.